메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

NEXTBIOMEDICAL Secures Health Canada Approval for Nexsph…

SEOUL, South Korea, Jan. 29, 2026 -- NEXTBIOMEDICAL CO., LTD. (KOSDAQ: 389650), an innovative medical device company based in South Korea, announced today that Nexsphere-F™, the company's novel fast resorbable microsphere for musculoskeletal pain embolization has received approval from Health Canada. Nexsphere-F™ is a fast resorbable microsphere designed for musculoskeletal pain embolization. It temporarily occludes abnormal blood vessels associated with osteoarthritis-related pain using resorbable microspheres, inducing necrosis of pain-generating nerve cells wit
- 김갑성 기자
- 2026-01-29 22:00
MicuRx Announces FDA Clearance of IND Application to Proce…

FOSTER CITY, Calif., Jan. 29, 2026 -- MicuRx Pharmaceuticals, Inc. ("MicuRx"), a clinical-stage biopharmaceutical company focused on developing novel anti-infective therapies for drug-resistant bacterial infections, recently announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for MRX-5, enabling the company to initiate a Phase 2a clinical trial in patients with Mycobacterium abscessus pulmonary disease. M. abscessus pulmonary disease is a serious and prevalent non-tuberculous mycobacterial (NTM) infection assoc
- 김갑성 기자
- 2026-01-29 21:02
XtalPi Convenes Global Experts to Shape the Future of Molecu…

Global thought leaders presented cutting-edge research at the 2026 International Symposium on Molecular Glue Drug Discovery. XtalPi unveils the AI-driven XGlue™ platform to enable rapid, closed-loop molecular glue drug discovery. Cross-sector discussions emphasized the need for bridging gaps between academic research, industrial development, and clinical applications. SHANGHAI, Jan. 29, 2026 -- Recently, XtalPi, a global leader in AI- and robotics-powered drug discovery, successfully concluded its 2026 International Symposium on Molecular Glue Drug Discovery. The event
- 김갑성 기자
- 2026-01-29 21:00
Spectrum Dynamics Medical Receives FDA 510(k) Clearance fo…

SARASOTA, Fla., Jan. 29, 2026 -- Spectrum Dynamics Medical, a global leader in digital nuclear medicine imaging solutions, today announced that it has received FDA 510(k) clearance for Veritas.AI™ Noise Reduction, its advanced artificial intelligence platform designed to significantly enhance image quality, diagnostic confidence, and operational efficiency on the VERITON-CT® digital SPECT/CT system. Veritas.AI represents a major advancement in molecular imaging, leveraging a deep learning convolutional neural network (CNN) to intelligently reduce image noise while preservin
- 김갑성 기자
- 2026-01-29 21:00
Hope Rising in Hainan: International NUT Carcinoma Center L…

BOAO, China, Jan. 29, 2026 -- The International NUT Carcinoma Diagnosis and Treatment Center has been inaugurated at Boao International Hospital. Established through a collaboration between Boao International Hospital and Chongqing University Three Gorges Hospital, this center tackles the profound challenges of NUT carcinoma, a rare cancer known for diagnostic difficulty, limited treatments, and poor survival. The center is powered by a landmark Chinese breakthrough: NHWD-870, a novel, oral BET inhibitor, developed by biotech Zhejiang Wenda Pharma Technology Co., Ltd. Clinical data is promisi
- 김갑성 기자
- 2026-01-29 20:00
Ascletis Announces Positive Topline Results from Its Phase…

- Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label study - The exceptional efficacy of denifanstat (ASC40) observed in the Company's previously reported placebo-controlled Phase III trial coupled with a favorable safety profile in two Phase III trials provide a potential major break-through for the treatment of acne - New Drug Application for denifanstat (ASC40) for acne was recently accepted by the China National Medical Products Administration HONG KONG, Jan. 29, 2026
- 김갑성 기자
- 2026-01-29 19:00
Singapore hosts its first Global Health Film Festival, spotlightin…

[ 메디채널 김갑성 기자 ] The two-evening programme on 27-28 January at The Ngee Ann Kongsi Auditorium at the SingHealth Duke-NUS campus convened clinicians, students, policymakers and partners to focus on the importance of outbreak preparedness and planetary health SINGAPORE, Jan. 29, 2026 -- Singapore has hosted its first Global Health Film Festival, bringing together clinicians, students, policymakers and partners to examine some of the most pressing health challenges facing the region, from infectious disease preparedness to climate-related health risks. Organised by the Sin
- 김갑성 기자
- 2026-01-29 14:42
Ivonescimab Included in FirstWord Pharma's "The Drugs Tha…

HONG KONG, Jan. 29, 2026 -- Akeso, Inc. (9926.HK) is pleased to share that the international industry media FirstWord Pharma released its list titled "Spotlight On: The Drugs That Will Shape 2026", providing an in-depth analysis of 20 key drugs poised to define the trajectory of the global pharmaceutical industry and transform disease treatment paradigms in 2026 and beyond. Akeso/Summit Therapeutics' ivonescimab(PD-1/VEGF bispecific antibody) was selected for inclusion. It stands as the only drug on this list originating from a Chinese innovative pharmaceutical company's independent
- 김갑성 기자
- 2026-01-29 12:51
WuXi Biologics and Sinorda Biomedicine Enter Strategic Colla…

SHANGHAI, Jan. 29, 2026 -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and Sinorda Biomedicine today jointly announced a strategic collaboration for the development and manufacturing of SND006, a novel bispecific antibody, for the potential treatment of inflammatory bowel disease (IBD) and other autoimmune diseases. Under the agreement, Sinorda Biomedicine will leverage WuXi Biologics' extensive experience and manufacturing capabilities in biologics development and manufacturing to advance SND006's preclinic
- 김갑성 기자
- 2026-01-29 10:39
Bupa and Tencent Launch Hong Kong's First Palm-based…

[ 메디채널 김갑성 기자 ] AI-powered palm verification set to deliver seamless, contactless and hygienic check-in journeys for patients at Bupa's healthcare centres HONG KONG, Jan. 29, 2026 -- Tencent in collaboration with Bupa Hong Kong ("Bupa"), today officially launched Hong Kong's first palm verification check-in service for the healthcare sector. The innovative solution is set to offer customers a smarter, faster, and more seamless way to access care, while enhancing hygiene and convenience. The Express Check-in, a first-of-its-kind contactless c
- 김갑성 기자
- 2026-01-29 10:23

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2026-01-31_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 31일 13시 40분